Adicet Bio shares promising look at CAR-T for lupus, but stock drops anyway
Adicet Bio reported that its off-the-shelf CAR-T therapy improved symptoms for lupus patients in an early-stage study, and it plans to soon start a pivotal trial. The Bay Area company in ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.